Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

about

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

Item

http://www.wikidata.org/entity/Q46576587

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

@en

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

@nl

type

Item

label

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

@en

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

@nl

prefLabel

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

@en

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

@nl

P1476

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

@en

P2093

Kaatz GW

http://www.w3.org/2001/XMLSchema#string

Rybak MJ

http://www.w3.org/2001/XMLSchema#string

P2860

Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721

Mechanism of action of the oxazolidinone antibacterial agents

Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

Nephrotoxicity of vancomycin, alone and with an aminoglycoside

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.

In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial.

Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options.

Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae.

Safety and tolerability of quinupristin/dalfopristin: administration guidelines.

P304

43-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.6.1.43

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2001-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15989495

http://www.w3.org/2001/XMLSchema#string

P921

Gram-positive bacteria